Compare Inovio Pharmaceuticals Inc (INO) vs IQIYI Inc - ADR (IQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs IQIYI Inc - ADR — how do they compare? Inovio Pharmaceuticals Inc trades at $0.77 (market cap $78.55M), while IQIYI Inc - ADR trades at $1.35 (market cap $1.30B). The key difference: IQIYI Inc - ADR is far larger — about 16.5× Inovio Pharmaceuticals Inc's market cap, and IQIYI Inc - ADR is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| INO | IQ | |
|---|---|---|
Market Cap | $78.55M | $1.30B |
Sector | Health | Media |
52-Week High | $2.87 | $2.79 |
52-Week Low | $0.66 | $0.96 |
Enterprise Value | $49.56M | $2.88B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $0.76, up 2.74% today, but remains in a bearish technical trend. The company shows minimal revenue of $65K against high operating losses, with a net income margin of -130,000%. Recent quarterly EPS has beaten expectations. Analyst consensus is bullish with a $3.25 price target, but the stock faces significant fundamental challenges including negative cash flow and high valuation multiples.
The outlook hinges on FDA approval of INO-3107 in October 2026, a binary event that could drive substantial upside. However, persistent cash burn, negative profitability, and ongoing shareholder litigation present high risks. Investors should weigh the potential catalyst against the company's weak financial health and operational execution challenges.
IQ (iQIYI) trades at $1.33, down 2.21% today, with a bullish technical signal from moving averages but overbought RSI readings. Revenue declined to $27.29B in 2025, with a net loss of $206.31M, though the company beat EPS expectations in two recent quarters. Recent news highlights AI platform growth and executive changes, while analyst sentiment is mixed with 50% buy ratings.
The outlook hinges on AI-driven content innovation and cost management to reverse profitability challenges, but risks include intense competition and regulatory pressures in China. Upside potential exists if execution improves, yet near-term volatility may persist amid earnings uncertainty and macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About IQIYI Inc - ADR
iQIYI Inc is an online entertainment service provider in China. It is primarily engaged in providing a variety of services encompassing internet video, live broadcasting, online games, online literature, animations, e-commerce, and social media platform. The company produces original video content and distributes appealing professionally produced content, partner-generated content, and user-generated content. It also offers a diverse collection of internet video content that appeals to users from broad demographics. The company's revenue is generated from membership services and online advertising services. The company earns most of its revenue from China.
Read more on IQ →
